Taxanes are widely used for many solid tumors, including metastatic breast cancer. Enhanced-delivery taxanes (EDTs) were specifically designed to improve the efficacy and tolerability of taxanes through the utilization of biocompatible, tumor-selective, taxane delivery vehicles, removing the need for drug delivery in toxic, conventional solvents. Nab-paclitaxel is a first-generation EDT that consists of paclitaxel encapsulated in albumin-bound nanoparticles that utilize a standard, endogenous serum albumin pathway to deliver paclitaxel to tumor cells. Second-generation EDTs, including Tocosol Paclitaxel (Sonus Pharmaceuticals, Inc., Bothell, Washington) and paclitaxel poliglumex, use biocompatible drug delivery vehicles that not only eliminate the need for toxic conventional solvents but also exploit tumor pathophysiological phenomena such as enhanced permeability and retention. Emerging evidence suggests that the use of EDTs may promote a more favorable and predictable pharmacokinetic profile with increased bioavailability of taxanes at the tumor site, limiting their exposure to normal tissues and improving the therapeutic benefits associated with taxane treatment.

中文翻译：

---

新型增强型交付紫杉烷：更新。

紫杉烷类被广泛用于许多实体瘤，包括转移性乳腺癌。增强递送紫杉烷类药物（EDT）是专门设计用于通过利用生物相容性，肿瘤选择性的紫杉烷类递送载体来提高紫杉烷类药物的功效和耐受性，从而无需在有毒的常规溶剂中进行药物递送。Nab-紫杉醇是第一代EDT，它由紫杉醇封装在白蛋白结合的纳米颗粒中组成，纳米颗粒利用标准的内源性血清白蛋白途径将紫杉醇递送至肿瘤细胞。第二代EDT，包括Tocosol紫杉醇（Sonus Pharmaceuticals，Inc.，华盛顿州博塞尔）和紫杉醇poliglumex，使用生物相容性药物传递载体，不仅可以消除对有毒常规溶剂的需要，而且可以利用肿瘤病理生理现象，例如增强的通透性和保留能力。新兴证据表明，EDTs的使用可能促进紫杉烷类在肿瘤部位的生物利用度的提高，从而促进更有利和可预测的药代动力学特征，限制其与正常组织的接触并改善与紫杉烷类治疗相关的治疗益处。